SanBio Company Limited
4592・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 3 directors (including 1 outside director), with an outside director ratio of approximately 33%. The Board of Corporate Auditors consists of 3 outside auditors. Neither a nomination committee nor a compensation committee has been established. One additional outside director is planned to be appointed at the Annual General Meeting of Shareholders in April 2026 (following the appointment, 2 of the 4 directors will be outside directors).
Risk Management
Operational risks are managed by the responsible departments, with a system in place to enable swift deliberation by the Executive Officers' Committee and the Board of Directors when risks materialize. For risks related to rapid technological innovation in regenerative medicine and side-effect risks, the company collaborates with its network of founding scientists. To address the risk of leakage of personal and corporate information, the company has established an Information Systems Management Regulation and a Confidential Information Management Regulation, and addresses such risks through access authority management and other measures. A system has also been built to collaborate with external experts such as lawyers, patent attorneys, and certified public accountants in the event of unforeseen circumstances.
Shareholder Returns
No dividend continues for FY2027 (ending January 2027). Full-year dividend forecast is ¥0.00 (both interim and year-end at ¥0.00). No change to the policy of prioritizing R&D investment.
Dividend Policy
The annual dividend forecast for FY2027 (ending January 2027) is ¥0.00 (¥0.00 at the second-quarter end and ¥0.00 at year-end). Actual results for the previous fiscal year (FY2026, ended January 2026) were also ¥0.00 annually. While recognizing shareholder returns as an important policy, there is no change to the policy of prioritizing the accumulation of internal reserves for R&D investment, and no dividend is expected to continue for the time being.
ESG
The Company's basic sustainability policy is to realize "a society in which everyone can achieve lifelong health and lead a rich and happy life." In terms of human resources, the Company promotes diversity, implementing hiring and promotion practices that are not constrained by gender or age. As of the end of January 2026, the Company had 33 employees (female ratio 21.2%), with a female ratio among managers of 57.1%. The Company has established a re-employment regulation (up to age 65) and a special specialist hiring system. No numerical targets have been set; instead, the Company confirms the absence of discrimination through internal audits. No quantitative disclosures related to climate change are included in the Annual Securities Report.
Last updated: April 20, 2026